A new study has identified a common pattern of immune response in Ebola-infected monkeys 4 days prior to the development of fever; this response could be utilized as an early diagnosis biomarker.
Browsing: Emerging Disease > Ebola
Researchers have identified that the Ebola virus recruits a host enzyme, PP2A-B56, for replication, demonstrating that inhibiting this pathway could be a target for drug discovery.
Researchers have reported an acceptable safety and immunogenicity profile of an Ebola vaccine in adults and potentially in children in Africa – indicating that the vaccine produces an immune response and is considered safe.
Researchers have examined the cerebrospinal fluid in a small cohort of Ebola survivors, reporting that no viral RNA was present and suggesting the virus may be cell-associated within the CNS.
A live-attenuated Ebola vaccine has demonstrated promising results in a Phase I randomized controlled trial assessing safety and immunogenicity, according to a Canadian study.
Author, Mark Woolhouse, discusses recent efforts to identify pathogens with pandemic potential and his own work on emerging viruses.
Researchers examining post-Ebola syndrome have discovered ocular consequences, including a disease-associated retinal scar.
John-Arne Røttingen discusses his role as founding CEO of the Coalition for Epidemic Preparedness Innovations (CEPI) and his thoughts on the importance of developing new vaccines for emerging threats.